BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) have revolutionized malignant melanoma treatment, offering high response and survival rates in patients with specific mutations.
• Despite targeted action, TKIs cause various adverse events (AEs), primarily dermatological, impacting patient quality of life.

Purpose of the Study:

• To review common adverse events (AEs) associated with BRAF, MEK, and KIT inhibitors used in malignant melanoma treatment.
• To provide guidance on managing these AEs to prevent treatment interruption or dose reduction.

Main Methods:

• Literature review of common AEs for BRAF, MEK, and KIT inhibitors in melanoma.
• Analysis of AE management strategies to maintain treatment efficacy and patient well-being.

Main Results:

• Common AEs include skin toxicities, which are generally mild to moderate but can affect quality of life.
• BRAF inhibitors are contraindicated in patients with a history of RAS-mutant tumors.

Conclusions:

• Effective management of TKI-induced AEs is essential for optimizing treatment outcomes in malignant melanoma.
• Clinicians require comprehensive knowledge of AE profiles and management strategies for BRAF, MEK, and KIT inhibitors.